These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 33373997)

  • 1. Addressing the drug-resistant tuberculosis challenge through implementing a mixed model of care in Uganda.
    Kasozi S; Kirirabwa NS; Kimuli D; Luwaga H; Kizito E; Turyahabwe S; Lukoye D; Byaruhanga R; Chen L; Suarez P
    PLoS One; 2020; 15(12):e0244451. PubMed ID: 33373997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive-phase treatment outcomes among hospitalized multidrug-resistant tuberculosis patients: results from a nationwide cohort in Nigeria.
    Oladimeji O; Isaakidis P; Obasanya OJ; Eltayeb O; Khogali M; Van den Bergh R; Kumar AM; Hinderaker SG; Abdurrahman ST; Lawson L; Cuevas LE
    PLoS One; 2014; 9(4):e94393. PubMed ID: 24722139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mycobacterium tuberculosis Uganda II family and resistance to first-line anti-tuberculosis drugs in Uganda.
    Ezati N; Lukoye D; Wampande EM; Musisi K; Kasule GW; Cobelens FG; Kateete DP; Joloba ML
    BMC Infect Dis; 2014 Dec; 14():703. PubMed ID: 25523472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National scale-up of tuberculosis-human immunodeficiency virus collaborative activities in Myanmar from 2005 to 2016 and tuberculosis treatment outcomes for patients with human immunodeficiency virus-positive tuberculosis in the Mandalay Region in 2015.
    Theingi P; Harries AD; Wai KT; Shewade HD; Saw S; Win T; Thein S; Kyi MS; Nyunt Oo H; Aung ST
    Trans R Soc Trop Med Hyg; 2017 Sep; 111(9):402-409. PubMed ID: 29361150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
    Umanah T; Ncayiyana J; Padanilam X; Nyasulu PS
    BMC Infect Dis; 2015 Oct; 15():478. PubMed ID: 26511616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis.
    Chem ED; Van Hout MC; Hope V
    BMC Infect Dis; 2019 Aug; 19(1):723. PubMed ID: 31420021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistant tuberculosis in HIV-infected patients in a national referral hospital, Phnom Penh, Cambodia.
    Walls G; Bulifon S; Breysse S; Daneth T; Bonnet M; Hurtado N; Molfino L
    Glob Health Action; 2015; 8():25964. PubMed ID: 25623609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
    BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary management of difficult-to-treat drug resistant tuberculosis: a review of cases presented to the national consilium in Uganda.
    Baluku JB; Katuramu R; Naloka J; Kizito E; Nabwana M; Bongomin F
    BMC Pulm Med; 2021 Jul; 21(1):220. PubMed ID: 34246234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa.
    Cox H; Hughes J; Daniels J; Azevedo V; McDermid C; Poolman M; Boulle A; Goemaere E; van Cutsem G
    Int J Tuberc Lung Dis; 2014 Apr; 18(4):441-8. PubMed ID: 24670700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.
    Hafkin J; Modongo C; Newcomb C; Lowenthal E; MacGregor RR; Steenhoff AP; Friedman H; Bisson GP
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):348-53. PubMed ID: 23321297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013.
    Chingonzoh R; Manesen MR; Madlavu MJ; Sopiseka N; Nokwe M; Emwerem M; Musekiwa A; Kuonza LR
    PLoS One; 2018; 13(8):e0202469. PubMed ID: 30133504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study.
    Bastard M; Sanchez-Padilla E; du Cros P; Khamraev AK; Parpieva N; Tillyashaykov M; Hayrapetyan A; Kimenye K; Khurkhumal S; Dlamini T; Perez SF; Telnov A; Hewison C; Varaine F; Bonnet M
    PLoS One; 2018; 13(3):e0193491. PubMed ID: 29518098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa.
    Yuengling KA; Padayatchi N; Wolf A; Mathema B; Brown T; Horsburgh CR; OʼDonnell MR
    J Acquir Immune Defic Syndr; 2018 Dec; 79(4):474-480. PubMed ID: 30212394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of tuberculosis patients in the integrated tuberculosis control model in Chongqing, China: a retrospective study.
    Zhang L; Xing W; Zhou J; Zhang R; Cheng Y; Li J; Wang G; Liu S; Li Y
    BMC Infect Dis; 2020 Aug; 20(1):576. PubMed ID: 32758169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.